Evidence map›Paper›PMID 32533515›Full record

ArticleInternational journal of hematology2020

Alternative splicing of APOBEC3D generates functional diversity and its role as a DNA mutator.

Hisashi Takei, Hirofumi Fukuda, Gilbert Pan, Hiroyuki Yamazaki, Tadahiko Matsumoto, Yasuhiro Kazuma, Masanori Fujii, Sohei Nakayama, Ikei S Kobayashi, Keisuke Shindo and 4 more

Open access · greenAbstract read
In one paragraph

Article in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Hisashi TakeiDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, E/CLS-407, 330 Brookline Avenue, Boston, MA, 02215, USA.
Hirofumi FukudaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Gilbert PanDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, E/CLS-407, 330 Brookline Avenue, Boston, MA, 02215, USA.
Hiroyuki YamazakiDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Tadahiko MatsumotoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Yasuhiro KazumaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Masanori FujiiDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, E/CLS-407, 330 Brookline Avenue, Boston, MA, 02215, USA.
Sohei NakayamaDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, E/CLS-407, 330 Brookline Avenue, Boston, MA, 02215, USA.
Ikei S KobayashiDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, E/CLS-407, 330 Brookline Avenue, Boston, MA, 02215, USA.
Keisuke ShindoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Riu YamashitaDivision of Translational Informatics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.
Kotaro ShirakawaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Akifumi Takaori-KondoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Susumu S KobayashiDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, E/CLS-407, 330 Brookline Avenue, Boston, MA, 02215, USA. skobayas@bidmc.harvard.edu.ORCID http://orcid.org/0000-0003-2262-4001
Kyoto University · JPBeth Israel Deaconess Medical Center · USNational Cancer Center Hospital East · JP

Funding

Overcoming resistance to tyrosine kinase inhibitors in lung cancerR01CA169259 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KOBAYASHI, SUSUMU · 2013 to 2018
$1.8M
Emergence of drug resistant mutations in lung cancerR21CA178301 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KOBAYASHI, SUSUMU · 2015 to 2016
$435k
American Cancer Society RSG-13-047Harvard Stem Cell Institute DP-0110-12-00NCCDPHP CDC HHS R01 DP000110NCI NIH HHS R01 CA169259NCI NIH HHS R21 CA178301NIH HHS R01CA169259NIH HHS R21CA178301
6 · The paper itself

Abstract

The apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC) protein family members have cytidine deaminase activity and can induce cytosine to uracil transition in nucleic acid. The main function of APOBEC3 (A3) proteins is to trigger an innate immune response to viral infections. Recent reports have shown that several APOBEC family proteins such as A3B can induce somatic mutations into genomic DNA and thus promote cancer development. However, the role of A3D on somatic mutations is unclear. Here, we identified the alternative splicing of A3D, and investigated each splice variant's subcellular localization and role in DNA mutagenesis. We identified four A3D variants, which all have one or two cytidine deaminase domains. The full-length form of A3D (variant 1) and truncated forms of A3D (variant 2, 6, 7) showed the ability to induce C/G to T/A transitions in foreign DNA and genomic DNA and retained antiretroviral activity. Furthermore, we demonstrated that A3D and A3B could induce deletions that are possibly repaired by microhomology-mediated end joining (MMEJ). Taken together, our experiments illustrated that alternative splicing generates functional diversity of A3D, and some variants can act as DNA mutators in genomic DNA.

Indexed as

Alternative SplicingAnti-Retroviral AgentsCell Line, TumorCells, CulturedCytidine DeaminaseDNADNA End-Joining RepairGenetic VariationHumansMutationProtein DomainsAnti-Retroviral AgentsAPOBEC3D protein, humanCytidine DeaminaseDNAApolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3D (APOBEC3D)Cytidine deaminaseLeukemiaMutationsResistance

Identifiers

PMID32533515
PMCPMC8713138
OpenAlexW3035180457

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.